These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

217 related items for PubMed ID: 15470221

  • 1. Prevention of hepatocellular carcinoma.
    Wands JR.
    N Engl J Med; 2004 Oct 07; 351(15):1567-70. PubMed ID: 15470221
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Lamivudine for patients with chronic hepatitis B and advanced liver disease.
    Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, Tanwandee T, Tao QM, Shue K, Keene ON, Dixon JS, Gray DF, Sabbat J, Cirrhosis Asian Lamivudine Multicentre Study Group.
    N Engl J Med; 2004 Oct 07; 351(15):1521-31. PubMed ID: 15470215
    [Abstract] [Full Text] [Related]

  • 4. Risk assessment for the development of hepatocellular carcinoma: according to on-treatment viral response during long-term lamivudine therapy in hepatitis B virus-related liver disease.
    Eun JR, Lee HJ, Kim TN, Lee KS.
    J Hepatol; 2010 Jul 07; 53(1):118-25. PubMed ID: 20471129
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Prevention and surveillance of hepatitis B virus-related hepatocellular carcinoma.
    Liaw YF.
    Semin Liver Dis; 2005 Jul 07; 25 Suppl 1():40-7. PubMed ID: 16103980
    [Abstract] [Full Text] [Related]

  • 7. Prevention of hepatocellular carcinoma: the holy grail of hepatitis B treatment.
    Sherman M.
    J Hepatol; 2009 May 07; 50(5):854-6. PubMed ID: 19303162
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Recent progress and new trends in the treatment of hepatitis B.
    Alberti A, Brunetto MR, Colombo M, Craxì A.
    J Med Virol; 2002 Jul 07; 67(3):458-62. PubMed ID: 12116046
    [Abstract] [Full Text] [Related]

  • 13. Can antiviral therapy for chronic hepatitis B enhance the progression to hepatocellular carcinoma?
    Warner N, Locarnini S.
    Antivir Ther; 2009 Jul 07; 14(2):139-42. PubMed ID: 19430088
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Events occurring at the time of breakthrough hepatitis during lamivudine treatment for chronic hepatitis B.
    Yokosuka O.
    J Gastroenterol; 2004 Aug 07; 39(8):813-4. PubMed ID: 15338383
    [No Abstract] [Full Text] [Related]

  • 16. Does treatment with interferon-based therapy improve the natural history of chronic hepatitis B infection?
    Lau GK.
    J Hepatol; 2007 Jan 07; 46(1):6-8. PubMed ID: 17112628
    [No Abstract] [Full Text] [Related]

  • 17. End points of therapy in chronic hepatitis B.
    Ahmed SN, Ecochard M, Zoulim F.
    Expert Rev Gastroenterol Hepatol; 2010 Feb 07; 4(1):37-49. PubMed ID: 20136588
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Chronic hepatitis B, biological basis for new therapeutic strategies.
    Dianzani F.
    J Biol Regul Homeost Agents; 1999 Feb 07; 13(2):71-9. PubMed ID: 10503729
    [No Abstract] [Full Text] [Related]

  • 20. [Lamivudine treatment consensus from relative experts in 2003].
    Lamivudine Clinical Practice Group.
    Zhonghua Gan Zang Bing Za Zhi; 2003 Aug 07; 11(8):497-9. PubMed ID: 12939188
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.